Nectar Lifesciences Limited (NECLIFE) fair value: what the stock is really worth
We calculate from audited financials what Nectar Lifesciences Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Nectar Lifesciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹9.30 – ₹53.92 · fair‑value band ₹7.26 – ₹13.75 · the ₹11.50 price screens above the ₹11.00 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally.
Show more
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Stock analysis
Nectar Lifesciences Limited (NECLIFE) currently trades at ₹11.50, while our model-based Fair Value estimate is ₹11.00, implying the stock looks roughly 4.5% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹7.26 (bear) to ₹13.75 (bull), the price of ₹11.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Nectar Lifesciences Limited reported revenue of ₹20.1M in FY2026 versus ₹16.7B in FY2022, a compound −81.4%/yr. Reported net income was −₹2.9B in FY2026.
Key figures
Market cap ₹2.3B (≈ $24.3M) · P/S ratio 24.9 · EPS (TTM) ₹−2.62 · Dividend yield 0.4% · Return on equity −7.5% · Return on assets (EBIT) 1.6% · Operating margin −673% · Revenue growth (YoY) −98.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −4%, NECLIFE screens cheaper than that median.
Fair Value models
Bear ₹7.26Fair Value ₹11.00Bull ₹13.75
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−89.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.5%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.0% (2021) → −2,936.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Nectar Lifesciences Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−10% · Above median
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)0% · Below median
Growth and dividend
Revenue growth−98% · Bottom 25%
Dividend yield (TTM)0.4% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Nectar Lifesciences Limited (NECLIFE) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹11.00 versus a price of ₹11.50, about −4% upside (fairly valued).
What is the fair value of NECLIFE?
Our model-based fair value for Nectar Lifesciences Limited is ₹11.00 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹11.50.
What is the quality score of NECLIFE?
Nectar Lifesciences Limited has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nectar Lifesciences Limited (NECLIFE)?
Our model-based price target is the fair value of ₹11.00 (as of Sep 13, 2026) from 3 valuation models. Cautious scenario ₹7.26, optimistic scenario ₹13.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Nectar Lifesciences Limited stock forecast for 2026?
Our models put fair value at ₹11.00, about −4% upside versus a price of ₹11.50 (fairly valued). Cautious scenario ₹7.26, optimistic scenario ₹13.75. The calculation is refreshed regularly with new filings.
Does Nectar Lifesciences Limited pay a dividend?
Nectar Lifesciences Limited currently shows a dividend yield of about 0.44% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Nectar Lifesciences Limited (NECLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nectar Lifesciences Limited it is ₹11.00 per share (as of Sep 13, 2026), against a price of ₹11.50. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Nectar Lifesciences Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, NECLIFE trades above its calculated fair value: price ₹11.50, fair value ₹11.00, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NECLIFE?
No. The price is what the market pays today (₹11.50); the fair value is what the company's own numbers justify (₹11.00). For Nectar Lifesciences Limited the two are ₹0.5000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nectar Lifesciences Limited worth?
The market values Nectar Lifesciences Limited at about ₹2.3B (market capitalisation, as of Sep 13, 2026). Per share that is ₹11.50; our models calculate a fair value of ₹11.00 per share.
What do the bullish and bearish scenarios say about NECLIFE?
Our models span a range for Nectar Lifesciences Limited: cautious scenario ₹7.26, base ₹11.00, optimistic ₹13.75 per share (as of Sep 13, 2026, price ₹11.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nectar Lifesciences Limited (NECLIFE)?
Balance-sheet figures for Nectar Lifesciences Limited (as of Sep 13, 2026): return on equity −7.5%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is NECLIFE from its 52-week high?
Nectar Lifesciences Limited trades at ₹11.50, about 51% below its 52-week high of ₹23.38 and 24% above the low of ₹9.30 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹11.00 is for.
Which stocks are comparable to Nectar Lifesciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nectar Lifesciences Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹11.50, calculated fair value ₹11.00 (−4%), Quality Score 39/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NECLIFE calculated?
We run Nectar Lifesciences Limited through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹11.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Nectar Lifesciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Nectar Lifesciences Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹7.26 to ₹13.75) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Nectar Lifesciences Limited
How large is the market capitalisation of Nectar Lifesciences Limited (NECLIFE)?
The market capitalisation of Nectar Lifesciences Limited is ₹2.3B (≈ $24.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nectar Lifesciences Limited (NECLIFE)?
The price-to-sales ratio of Nectar Lifesciences Limited is 24.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nectar Lifesciences Limited (NECLIFE)?
Earnings per share at Nectar Lifesciences Limited are ₹−2.62. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nectar Lifesciences Limited (NECLIFE)?
The dividend yield of Nectar Lifesciences Limited is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Nectar Lifesciences Limited (NECLIFE)?
The return on equity (ROE) of Nectar Lifesciences Limited is −7.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nectar Lifesciences Limited (NECLIFE)?
On an EBIT basis the return on assets of Nectar Lifesciences Limited is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nectar Lifesciences Limited (NECLIFE)?
The operating margin of Nectar Lifesciences Limited is −673% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nectar Lifesciences Limited (NECLIFE)?
Revenue at Nectar Lifesciences Limited is growing −98.2% versus a year earlier (3y avg −89.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nectar Lifesciences Limited (NECLIFE)?
Earnings per share at Nectar Lifesciences Limited are growing +82.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nectar Lifesciences Limited (NECLIFE) generate?
The free cash flow of Nectar Lifesciences Limited is −₹3.6B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nectar Lifesciences Limited (NECLIFE) hold?
Nectar Lifesciences Limited holds more cash than debt, ₹1.1B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Nectar Lifesciences Limited in the live analysis
One click puts Nectar Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
